Home/Organon/Jennifer Halchak
JH

Jennifer Halchak

Head of Strategy and Business Development

Organon

Organon Pipeline

DrugIndicationPhase
AYA™ (etonogestrel) contraceptive vaginal systemContraceptionFiled
MK-8189 (deudomperidone)Vasomotor symptoms due to menopausePhase 3
Biosimilar to Stelara® (ustekinumab)Immunology (e.g., plaque psoriasis, Crohn's disease)Phase 3
Biosimilar to Eylea® (aflibercept)Ophthalmology (neovascular AMD)Phase 3
Biosimilar to Prolia®/Xgeva® (denosumab)Bone health / OncologyPhase 3
Biosimilar to Simponi® (golimumab)Immunology (e.g., rheumatoid arthritis)Phase 3